Letrozole Tablet
Product Images NDC 63850-0025

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 63850-0025). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Natco Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Letrozole Chemical Structure (Letro.fig1)

Chemical structure of letrozole, depicted with two aromatic rings each attached to a cyano group and connected to a central triazole ring.*

FDA Label Image

Letrozolefig (Letro.fig2)

A survival curve chart comparing Letrozole and Tamoxifen treatments over a 72-month period. The graph plots disease-free survival (DFS) probabilities on the vertical axis against time in months on the horizontal axis, showing event counts and patient numbers at risk for both treatments during the study.*

FDA Label Image

Letrozole Graph (Letro.fig3)

A line graph depicting progression-free survival over months for Letrozole tablets 2.5 mg compared to tamoxifen 20 mg. The vertical axis represents progression-free proportion ranging from 0 to 1, and the horizontal axis represents time in months up to 60. Two lines show changes over time for each treatment.*

FDA Label Image

Letrozole Graph (Letro.fig4)

A survival curve graph comparing the proportion of patients alive over a period of 60 months between two treatment groups: letrozole first and tamoxifen first. The x-axis represents time in months, and the y-axis shows the proportion alive, with letrozole depicted by a solid line and tamoxifen by a dashed line.*

FDA Label Image

Letrozole Graph (Letro.fig5)

A line graph depicting time to progression (in days) for two treatment groups: letrozole tablets 0.5 mg and letrozole tablets 2.5 mg. The graph shows survival curves comparing the progression-free times between these dosage groups over approximately 1000 days.*

FDA Label Image

Letrozole Graph (Letro.fig6)

A Kaplan-Meier survival curve chart showing time to progression in days for different treatment groups. Three lines represent letrozole tablets at 0.5 mg, 2.5 mg, and a third group (AG). The x-axis shows time to progression up to 1000 days, and the y-axis shows the proportion of subjects without progression from 0 to 1.0.*

FDA Label Image

Letrozole Tablets 2.5 mg- Bottle Of 30 Container Label (Letro.fig7)

Packaging label for Letrozole Tablets USP 2.5 mg, oral tablets, in a 30 count package. The label indicates the product is manufactured by Natco Pharma Limited. It includes storage instructions at 25°C with permissible excursions and advises dispensing in a tight container. The label also notes to keep the medication out of the reach of children and provides a barcode and lot information space.*

FDA Label Image

Letrozole Tablets Bottle Of 1000s Label (Letro.fig8)

Packaging label for Letrozole Tablets, USP 2.5 mg by Natco Pharma Limited. This label is for a bottle containing 1000 oral film-coated tablets. Label includes storage instructions, prescription-only status, barcode, and manufacturer details from Kothur, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.